Pre-Sleep Creatine Enhances Anaerobic Power in Recreationally Active Females
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Creatine Monohydrate, Placebo (Maltodextrin).
- Who it may be relevant to
- Registry conditions: Anaerobic Performance, Sports Nutrition, Exercise Recovery, Muscle Fatigue. Basic parameters: 18 years — 25 years · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Iran
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
This study is a randomized, double-blind, placebo-controlled trial designed to examine the effects of pre-sleep creatine monohydrate supplementation on anaerobic performance and muscle damage markers in recreationally active females. Participants will be randomly assigned to receive either 5 grams of creatine monohydrate or a placebo 30 minutes before sleep for seven consecutive days. Anaerobic performance will be assessed using the Wingate Anaerobic Test, evaluating peak and average power output and fatigue index. Blood samples will be collected before and after the supplementation period to analyze markers of muscle damage, including creatine kinase and lactate dehydrogenase. This study aims to provide insight into the efficacy of short-term, time-specific creatine supplementation for enhancing performance and recovery.
Interventions
- Dietary supplement Creatine Monohydrate
Participants will receive 5 grams of creatine monohydrate powder dissolved in water, flavored with a sugar-free agent, 30 minutes before sleep each night for 7 days. - Dietary supplement Placebo (Maltodextrin)
Visually identical placebo (maltodextrin powder, 5 g/day), flavored with a sugar-free agent, dissolved in water and consumed 30 minutes before sleep for 7 consecutive days.
Primary outcome measures
- Average Power Output (Watts) - 30-Second Wingate Test [Time frame: Baseline and post-intervention (Day 0 and Day 7)]
Secondary outcome measures (4)
- Peak Power Output (Watts) - Wingate Test [Time frame: Baseline and post-intervention (Day 0 and Day 7)]
- Fatigue Index (%) - Wingate Test [Time frame: Baseline and post-intervention (Day 0 and Day 7)]
- Serum Creatine Kinase (CK) Activity [Time frame: Baseline and 24 hours post Wingate Test (Day 0 and Day 8)]
- Serum Lactate Dehydrogenase (LDH) Activity [Time frame: Baseline and 24 hours post Wingate Test (Day 0 and Day 8)]
Eligibility criteria
Inclusion criteria
Female, aged 18 to 25 years
Recreationally active (engaging in structured resistance training 3-4 times per week for the past 6 months)
Regular menstrual cycles (used for scheduling purposes)
Able and willing to provide informed consent
Agreement to maintain normal diet and training routines throughout the study
Exclusion criteria
History of musculoskeletal injury affecting lower or upper limbs within the past 6 months
Known allergy or intolerance to creatine or maltodextrin
Use of performance-enhancing substances or supplements within the last 30 days
Use of recovery modalities such as massage, cryotherapy, or compression garments during the study period
Current use of anti-inflammatory medication
Pregnancy or breastfeeding
Inability to comply with study protocol or scheduled assessments
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
Iran · 1 center
- Islamic Azad University, Shabestar Branch — Shabestar
Identifiers
NCT: NCT06937190 · 162593019